company

Johnson & Johnson

JNJJohnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson Taiwan Ltd
CIK 0000200406ticker JNJ
as of 2026-07-01
Monitor thisAsk about this
at a glance
Cash $21.7B (as of 2026-03-29)
Revenue $24.1B
89 trials sponsored · 16 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
Cash$21.7B2026-03-29
Ga Expense$6.0B2026-03-29
Net Income Loss$5.2B2026-03-29
Revenue$24.1B2026-03-29
Rnd Expense$3.5B2026-03-29
Stockholders Equity$81.2B2026-03-29
Total Assets$200.9B2026-03-29

Pipeline

16 assets
AripiprazoleOlanzapinePaliperidoneQuetiapineRisperidoneExtended-release galantamine hydrobromideJNJ-37822681JNJ-40411813KetamineOther atypical antipsychotic drugsR092670R209130Retrospective chart review studyRisperidal Constadivalproex sodium ERtopiramate

Recent filings

SEC EDGAR
11-Kopen ↗2026-06-25
11-Kopen ↗2026-06-25
4open ↗2026-06-12
4open ↗2026-06-11
4open ↗2026-06-11
4open ↗2026-06-11
144open ↗2026-06-11
SDopen ↗2026-05-27
13F-HRopen ↗2026-05-13
4open ↗2026-05-04
SCHEDULE 13Gopen ↗2026-05-01
8-Kopen ↗2026-04-28

Facts & assertions

8 sourced
Financial Status
profitable
Latest Cash
21,688,000,000
Latest Ga Expense
6,034,000,000
Latest Net Income Loss
5,235,000,000
Latest Revenue
24,062,000,000
Latest Rnd Expense
3,527,000,000
Latest Stockholders Equity
81,186,000,000
Latest Total Assets
200,894,000,000
relationships
The graph out of here
asset
Aripiprazole
small molecule
drug
Olanzapine
small molecule
drug
Paliperidone
small molecule
drug
Quetiapine
small molecule
drug
Risperidone
small molecule
drug
Extended-release galantamine hydrobromide
small molecule
drug
JNJ-37822681
small molecule
drug
JNJ-40411813
small molecule
drug